1316216-07-5

Basic information

• Product Name: 7-({2-[(1-Methyl-buta-1,3-dienyl)-phenyl-aMino]-pyriMidine-5-carbonyl}-aMino)-heptanoic acid Methyl ester
• Synonyms: 7-({2-[(1-Methyl-buta-1,3-dienyl)-phenyl-aMino]-pyriMidine-5-carbonyl}-aMino)-heptanoic acid Methyl ester;(E)-Methyl 7-(2-(penta-2,4-dien-2-yl(phenyl)aMino)pyriMidine-5-carboxaMido)heptanoate;7-[[[2-(diphenylamino)-5-pyrimidinyl]carbonyl]amino]Heptanoic acid methyl ester;KOLTWQICZYJIRV-XDHOZWIPSA-N;methyl 7-(2-(diphenylamino)pyrimidine-5-carboxamido)heptanoate
• CAS NO: 1316216-07-5
• Molecular Formula: C₂₅H₂₈N₄O₃
• Molecular Weight: 422.52
• EINECS: -0
• Mol File: 1316216-07-5.mol
• Article Data: 24

Chemical Properties

• Appearance: /
• Density: 1.180±0.06 g/cm3(Predicted)
• PKA: 13.61±0.46(Predicted)
• CAS DataBase Reference: 7-({2-[(1-Methyl-buta-1,3-dienyl)-phenyl-aMino]-pyriMidine-5-carbonyl}-aMino)-heptanoic acid Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 7-({2-[(1-Methyl-buta-1,3-dienyl)-phenyl-aMino]-pyriMidine-5-carbonyl}-aMino)-heptanoic acid Methyl ester(1316216-07-5)
• EPA Substance Registry System: 7-({2-[(1-Methyl-buta-1,3-dienyl)-phenyl-aMino]-pyriMidine-5-carbonyl}-aMino)-heptanoic acid Methyl ester(1316216-07-5)

Safety Data

• Hazardous Substances Data: 1316216-07-5(Hazardous Substances Data)

Usage

General Description

The chemical "7-({2-[(1-Methyl-buta-1,3-dienyl)-phenyl-aMino]-pyriMidine-5-carbonyl}-aMino)-heptanoic acid Methyl ester" is a methyl ester derivative of a compound with a complex structure containing a pyrimidine ring, a butadienyl-phenyl-amino group, and a heptanoic acid moiety. The compound is a derivative of heptanoic acid and is also known as aMino acid derivative. It is commonly used in research and pharmaceutical industries for various applications due to its unique chemical structure and potential biological activities.

Upstream product

• 591-50-4 iodobenzene 
• 95928-49-7 2-hydroxy-pyrimidine-5-carboxylic acid ethyl ester 
• 1316216-05-3 C₁₉H₁₇N₃O₂ 
• 864172-93-0 ethyl 2-(phenylamino)pyrimidine-5-carboxylate 
• 39979-08-3 methyl 7-aminoheptanoate 
• 1316216-06-4 C₁₇H₁₃N₃O₂ 
• 62-53-3 aniline 
• 89793-12-4 ethyl 2-chloropyrimidine-5-carboxylate 

Downstream Products

• 1316214-52-4 N-[7-(hydroxyamino)-7-oxo-heptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide 

Relevant articles and documents

PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND EPOTHILONE AND METHODS OF USE THEREOF

The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) an epothilone, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.

PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A BCL-2 INHIBITOR AND METHODS OF USE THEREOF

The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) a BCL-2 inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.

USE OF HDAC6 INHIBITORS FOR PREVENTING AND TREATING RENAL CYSTOGENESIS, RENAL CELL CARCINOMA, AND RENAL CILIOPATHIES

The present disclosure is directed to the use of HDAC6 inhibitors for the treatment of renal diseases and disorders, including ciliopathy, Von Hippel-Lindau (VHL) disease, renal cystogenesis, renal cell carcinoma, and Tuberous Sclerosis Complex (TSC), and the like. In some embodiments, the HDAC6 inhibitor is a direct inhibitor of HDAC6. In a further embodiment, the HDAC6 signaling inhibitor is ACY-1215 or a pharmaceutically acceptable salt thereof. In some embodiments, the HDAC6 inhibitor is combined with an AURKA inhibitor.